MBX Biosciences, Inc. Common Stock (MBX) Stock
NASDAQ · MBX
60.94
Fundamentals
Market cap
$3.03B
Price / Earnings ratio
-29.1x
Price / Sales ratio
N/A
Price / Book ratio
7.4x
Return on assets
-0.2%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About MBX Biosciences, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees63
CEOMr. Steven L. Hoerter
IPO DateSep 12, 2024
HeadquartersCarmel, IN
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven L. Hoerter | Executive Chairperson, CEO & President | 1971 |
| Dr. Salomon Azoulay M.D. | Chief Medical Officer | 1958 |
| Mr. John W. Smither CPA | Chief Financial Officer | 1953 |
| Mr. Pete De Spain | Senior Vice President of Investor Relations & Corporate Communications | — |
| Ms. Michelle Graham | Chief Human Resources Officer | 1967 |
| Dr. Michael A. Dorato DABT, Ph.D. | Sr. Vice President of Discovery & Non-Clinical Development | — |
| Dr. Chatan Charan Ph.D. | Senior VP of Pharmaceutical Development & Chemistry, Manufacturing and Controls | — |
| Mr. Mark Hope | Senior Vice President of Regulatory & Quality | — |
| Dr. Andreas Moraitis M.D. | Senior Vice President of Clinical Development | — |
| Ms. Karen Basbaum M.B.A. | Chief Business Officer | — |
Fundamentals
Valuation
Market cap$3.03B
Price-to-sales ratioN/A
Price-to-book value7.40
Price-earnings ratio-29.10
Return on Equity-25.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-2.36
Income Statement
Average volume464,625
EBITDA$-86.23M
1 year high (52w)$72.64
1 year low (52w)$12.94
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



